login
  Password reminder
Spinal News
Contact the editor Visit Spinal News Twitter feed Visit Spinal News Facebook page
 

Spinal Modulation Neurostimulator system receives CE mark for the management of chronic intractable pain


Monday, 12 Dec 2011 11:03
Spinal Modulation Neurostimulator system
Spinal Modulation Neurostimulator system


The Spinal Modulation Neurostimulator system (Spinal Modulation) has received CE mark for the management of chronic intractable pain. This system utilises low-level electrical signals to modulate neural structures of primary sensory neurons located within the dorsal root ganglion. These cell bodies have been implicated in the development and maintenance of chronic pain conditions.


Liong Liem and Paul Verrills presented the initial results of the world’s first multicentre prospective clinical trial to assess the management of chronic pain through stimulation of the dorsal root at the 15th Annual North American Neuromodulation Society (NANS) conference in Las Vegas, USA.

“The Spinal Modulation system has provided substantial benefit to a number of my patients with chronic intractable pain that have not had adequate pain relief with other spinal cord stimulation systems. For example, patients with chronic intractable pain in the lower extremities are typically very difficult to treat with existing spinal cord stimulation systems. With the Spinal Modulation system, I have seen very encouraging results in patients with this type of pain condition,” said Liem, director of the Pain Management Practice at Sint Antonius Hospital in The Netherlands.

Neurostimulation therapy is a proven method of managing chronic pain. It uses an implantable medical device to deliver mild electrical pulses to neural tissue to mask or interrupt pain signals as they travel to the brain. With dorsal column spinal cord stimulation, small wires are placed along the midline of the epidural space. With the Spinal Modulation therapy, physicians place a specialised neuromodulation system in the epidural space to target the dorsal root ganglion, which allows the signals to be masked or interrupted even before they enter the spinal cord.

“Spinal Modulation has taken a deliberate and scientific approach to developing this therapy. My practice has partnered with Spinal Modulation to help demonstrate the clinical utility of neuromodulation of the dorsal root ganglion in patients with chronic, intractable pain. I am very enthusiastic that they have developed practical and clinically useful tools for long-term stimulation of the dorsal root ganglion and I look forward to its commercial availability in my practice in Australia,” said Marc Russo, Director of the Hunter Pain Clinic in Newcastle, Australia.

The company has begun international commercialisation and plans to continue clinical research in order to advance dorsal root ganglion stimulation and provide pain relief for more patients.

The Spinal Modulation Neurostimulator system is not approved for use or sale in the United States.




Add New Comment

Most popular


Epidural glucocorticoid injections provide little or no benefit for spinal stenosis
Friday, 11 Jul 2014
A new study indicates that epidural injections of glucocorticoids and lidocaine provide little or no benefit compared with epidural injections of lidocaine alone for patients with lumbar spinal ... Epidural glucocorticoid injections provide little or no benefit for spinal stenosis

Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment
Wednesday, 23 Jul 2014
The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star (DFINE) tumour ... Trial shows significant pain relief for spine cancer patients following targeted radiofrequency ablation treatment

CE mark for FLXfit 3D expandable interbody cage
Tuesday, 01 Jul 2014
Expanding Orthopedics has announced that the FLXfit, its novel expandable and articulated TLIF cage with lordotic correction, has received CE mark approval and is now cleared for commercialisation in ... CE mark for FLXfit 3D expandable interbody cage

Features


The ASIA impairment scale for spinal injuries may show worsening despite neurological improvement
Thursday, 31 Jul 2014
Ibrahim Gündoğdu and colleagues report in Spinal Cord that the American Spinal Injury Association (ASIA) impairment scale is limited because it could show worsening despite a patient with a spinal ... The ASIA impairment scale for spinal injuries may show worsening despite neurological improvement

Can cognitive behavioural therapy help spinal surgery patients return to work and daily life?
Friday, 11 Jul 2014
Nanna Rolving and colleagues have launched a study to investigate the clinical effectiveness and cost-effectiveness of using a multidisciplinary cognitive behavioural intervention to help patients ... Can cognitive behavioural therapy help spinal surgery patients return to work and daily life?

Profiles


Lori Karol
Wednesday, 13 Aug 2014
Lori Karol, Texas Scottish Rite Hospital, Dallas, USA, talks to Spinal News International about the ... Lori Karol

Luiz Pimenta
Thursday, 12 Jun 2014
Luiz Pimenta, immediate past president of the International Society for the Advancement of Spinal S... Luiz Pimenta

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions